Studies have shown short-term effects of particulate pollution (PM) on hospital admissions and deaths from cardiovascular causes ([@b1-ehp0115-000769]; [@b6-ehp0115-000769]; [@b12-ehp0115-000769]; [@b23-ehp0115-000769]; [@b47-ehp0115-000769]; [@b51-ehp0115-000769]; [@b53-ehp0115-000769]; [@b64-ehp0115-000769]). Myocardial infarctions (MIs) have been shown to be susceptible to being triggered by PM ([@b6-ehp0115-000769]; [@b11-ehp0115-000769]; [@b30-ehp0115-000769]; [@b41-ehp0115-000769]; [@b59-ehp0115-000769]; [@b63-ehp0115-000769]). These studies have not addressed whether persons who survive an MI are at risk of death in response to subsequent particle exposure.

A few studies have addressed this question with respect to acute exposure. For example, [@b2-ehp0115-000769] reported subjects in Chicago who were discharged alive for an MI had twice the risk of death due to acute air pollution exposure as other subjects.

In a recent study of five European cities, [@b59-ehp0115-000769] found that ambient air pollution was associated with increased risk of hospital cardiac readmissions of MI survivors. [@b45-ehp0115-000769] examined the probability of recurrent hospitalization in a cohort of MI survivors; compared the use of time-series, case--crossover, and survival analysis for analyzing short-term health effects; and found that the three methods gave similar results. None of these studies examined the effect of longer-term exposure on survival.

Several studies have examined the effect of longer-term PM exposure on survival in general cohorts. The Harvard Six Cities Study ([@b13-ehp0115-000769]) demonstrated an association between mortality and chronic exposure to PM. A recent reanalysis of the Harvard Six Cities Study, which extended the mortality follow-up period, used a similar approach to our study and included PM~2.5~ (PM with aero-dynamic diameter \< 2.5 μm) as a time-varying exposure; [@b29-ehp0115-000769] found significant association of PM~2.5~ with mortality.

Two articles ([@b46-ehp0115-000769], [@b47-ehp0115-000769]) have shown an association between PM and mortality in the American Cancer Society (ACS) Cancer Prevention Study population, including an association between PM and deaths from all cardiovascular disease ([@b47-ehp0115-000769]).

These studies have treated air pollution as a city-level variable, whereas two European cohort studies have assessed exposure at an individual level. [@b19-ehp0115-000769] found an association between estimated long-term exposure to traffic-related particles at each participant's home and cause-specific mortality in the Netherlands Cohort Study on Diet and Cancer. [@b35-ehp0115-000769] found an association between estimated nitrogen dioxide concentrations at the subject's home and the risk of dying for total, respiratory, lung cancer, and ischemic heart disease mortality in a cohort of men in Oslo, Norway. Particle data was not available in that study, and NO~2~ was used as a marker of traffic pollution.

Although these studies have reported an association of PM with survival, they have not evaluated the role of preexisting cardiac disease or whether risk changed with annual changes in exposure, nor have they treated pollution as a time-varying covariate.

Reduced heart rate variability has been associated with decreased survival of MI patients ([@b14-ehp0115-000769]; [@b34-ehp0115-000769]), and PM has been associated with reduced heart rate variability ([@b9-ehp0115-000769]; [@b17-ehp0115-000769]; [@b32-ehp0115-000769]; [@b39-ehp0115-000769]; [@b49-ehp0115-000769]), which in turn is associated with decreased post-MI survival ([@b56-ehp0115-000769]). Other studies have suggested that PM may be associated with increased C-reactive protein ([@b7-ehp0115-000769]; [@b43-ehp0115-000769]), which is associated with mortality risk following an MI ([@b25-ehp0115-000769]). PM and its components have also been shown to increase oxidative stress in the heart ([@b5-ehp0115-000769]; [@b7-ehp0115-000769]; [@b10-ehp0115-000769]; [@b55-ehp0115-000769]), to decrease plaque stability ([@b57-ehp0115-000769]), and to increase atherosclerosis ([@b28-ehp0115-000769]). Based on this, we investigated whether annual PM exposure was associated with progression of disease or reduced survival in a study of 196,000 persons discharged alive following an acute MI.

Materials and Methods
=====================

Study population
----------------

Using Medicare data for persons ≥ 65 years of age, we constructed a cohort of survivors of acute MI, defining cases as emergency admissions for a primary discharge diagnosis of MI \[*International Classification of Diseases, Ninth Revision* (ICD-9; [@b61-ehp0115-000769]) code 410\] discharged alive between 1985 and 1999 in any of 21 cities chosen to represent a broad range of the country. We obtained from Medicare the date of death for each subject, or whether they were still alive as of the end of 1999. We also retrieved information on age, sex, race, and the number of coronary intensive care days and Medical intensive care days.

To study progression of disease, we traced each subject through subsequent Medicare records and identified admissions for a subsequent MI or for congestive heart failure (CHF; ICD-9 code 428).

Subjects alive the first of January of the year following the admission were entered into the cohort, and follow-up periods were calendar years. We excluded subjects whose death or subsequent admission occurred within the first 3 months of their index admission.

We also used a unique identifier for each subject to assess medical factors that might modify the risk of survival or progression, such as whether they had any primary or secondary diagnosis of chronic obstructive pulmonary disease (COPD; ICD-9 codes 490--496, except 493), diabetes (ICD-9 code 250), or essential hypertension (ICD-9 code 401); or if they had previous admissions for atrial fibrillation (ICD-9 code 427.3).

During 1985--1999 changes in treatment occurred, such as introduction of thrombolytics and increased angioplasty. To control for changes in postdischarge survival, we used strata to allow a different underling hazard for each 5-year interval in the study.

We defined a categorical variable for type of MI as given by the fourth digit of the ICD-9 code. There are 10 different types of MI: ICD-9 code 410.0, MI of anterolateral wall; 410.1, other anterior wall; 410.2, inferolateral wall; 410.3, inferoposterior wall; 410.4, other inferior wall; 410.5, other lateral wall; 410.6, true posterior wall infarction; 410.7, subendocardial infarction; 410.8, other specified sites; and 410.9, unspecified sites.

City characteristics, such as population density and percentage of population ≥ 65 years of age in poverty status, were obtained from the 1990 U.S. census ([@b58-ehp0115-000769]). The average annual mortality rate for emphysema among people ≥ 65 years of age during 1989--2000 were obtained from the National Center for Health Statistics (Hyattsville, MD) and used as an indirect measure of smoking history in each city.

The accuracy of the Medicare claims-based diagnosis of MI has been recently validated ([@b26-ehp0115-000769]).

Environmental data
------------------

We obtained data for PM~10~ (particulate air matter with aero-dynamic diameter \< 10 μm) for 1985--1999 from the U.S. Environmental Protection Agency's Aerometric Information Retrieval System ([@b36-ehp0115-000769]).

We selected the following cities with daily PM~10~ monitoring that represent a geographic distribution across the country: Birmingham, Alabama; Boulder, Colorado; Canton, Ohio; Chicago, Illinois; Cincinnati, Ohio; Cleveland, Ohio; Colorado Springs, Colorado; Columbus, Ohio; Denver, Colorado; Detroit, Michigan; Honolulu, Hawaii; Houston, Texas; Minneapolis-St.Paul, Minnesota; Nashville, Tennessee; New Haven, Connecticut; Pittsburgh, Pennsylvania; Provo-Orem, Utah; Salt Lake City, Utah; Seattle, Washington; Steubenville, Ohio; and Youngstown, Ohio.

For most cities, the metropolitan county encompassed the city and much of its suburbs, but we used multiple counties for Minneapolis-St. Paul (Ramsey and Hennepin), Birmingham (Blount, Jefferson, St. Clair, Shelby, and Walker), Steubenville (Jefferson, OH; Brooke and Hancock, WV), and Youngstown (Columbiana and Mahoning).

For each subject and follow-up period we created yearly averages (January--December) of pollution for that year and lags up to the 3 previous years.

Analytical strategy
-------------------

We defined the cohort as follows: We assumed that a subject admitted for MI enters the cohort if he survived at least 3 months and/or is alive the first January of the year following the admission. For each subject, the follow-up periods were 1 year periods (January--December) until the year in which they die (or suffer a subsequent MI or CHF admission for those analyses) or until December 1999 (censoring).

City-specific cohorts were created for the three survival analyses, one where failure was defined as death, one where failure was defined as a new MI, and one where failure was defined as a first admission for CHF.

We analyzed the data with an extended Cox's proportional hazard regression model, which allows for time-varying covariates in survival analysis ([@b27-ehp0115-000769]). The model for the hazard *h* at time *t* is
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where *t* is time since a subject entered the cohort (January) after the admission for MI and is represented by 1 year; *X*~1~, ... *X*~p1~ are time-invariant variables such as sex; and *Z*~1~(*t*),..., *Z*~p2~(*t*) are time-varying variables such as air pollution.

We adjusted for individual risk factors including age, sex, race, type of MI, number of days of coronary care and intensive care, previous diagnoses for atrial fibrillation, and secondary or previous diagnoses for COPD, diabetes, and hypertension, and for season of initial event as cold (December--February), hot (June--August), and transitional. To allow for possible nonproportionality of the survival rates, time period (three categories: 1985--1989--1990--1994, and 1995--1999), age (5-year categories), sex, race (white, black, others), and type of MI (10 categories) were treated as stratification variables.

Ties were treated using the approach of [@b21-ehp0115-000769].

As a sensitivity analysis, we considered an alternative definition of our follow-up period. We defined yearly follow-up (and exposure averages) using a 12-month period starting the month of their index admission. We continued to construct 12-month average PM exposure for each subject for each subsequent year of follow-up (using month of initial event as the anniversary) until censoring or failure. In the last follow-up period for each subject, the person time at risk was \< 12 months, and this was incorporated in the model. However, PM exposure was kept as a 12-month average to maintain comparability with other periods. When the last follow-up period was ≤ 3 months, subjects were censored at their last complete 12-month period of follow-up because the exposure interval was judged too short to be comparable to the 12-month exposure used for the follow-up periods.

We also restricted the mortality and CHF cohorts to subjects with a second MI, with follow-up beginning after the occurrence of their second MI, or including only those subjects who were admitted for their primary MI between 1985 and 1996, allowing at least 3 years of follow-up to all subjects in the analysis.

For each subject in each follow-up period, we considered the following possible exposure indexes: *a*) the average PM~10~ in their city in that follow-up period; and *b*) a model containing simultaneously the exposure during the follow-up period and each of the three previous years (distributed lag), to see if we could determine how the PM dropped off over time.

We first performed city-specific analyses; in the second stage of the analysis, the results were combined using the meta-regression technique of [@b4-ehp0115-000769]. To be conservative, we report the results incorporating a random effect, whether or not there was a significant heterogeneity.

Effect modification by individual risk factors was examined by fitting separate proportionate hazard models for each group (e.g., sex) in each city, controlling for covariates and combining across cities as in the main analysis. In addition, we examined effect modification by city characteristics by entering them as predictor variables in the meta-regression. These included measures of socioeconomic condition (percent in poverty), exposure-related measures (mean and interquartile range of PM~10~ in the city), general social factors (population density), and the emphysema death rate in persons ≥ 65 years of age as a surrogate for the smoking history of the population. The results are expressed as hazard ratio (HR) for 10 μg/m^3^ PM~10~.

Results
=======

There were 196,131 eligible MIs in the 21 cities during the study period. [Table 1](#t1-ehp0115-000769){ref-type="table"} shows characteristics of the study population for all the cities. Of the population, 45.5% died by the end of follow-up, 17% had a CHF admission after the index MI, and 11.5% had a subsequent MI. In the cohort, 63% of the subjects were ≥ 75 years of age. The most common types of MI were sub-endocardial infarction (34%), MI of other inferior wall (23%), and MI of other anterior wall (19%).

The average duration of the follow-up was 5.1 years for mortality, 3.7 years for CHF, and 3.6 years for subsequent MI. The range of survival times in all the cohorts varied from 1 to 14 years.

[Table 2](#t2-ehp0115-000769){ref-type="table"} presents city-specific characteristics, including the total population, PM concentrations, counts of hospital admissions for MI, and the numbers of deaths, subsequent acute MI, and first hospitalizations for CHF. The average PM~10~ across all cities was 28.8 μg/m^3^.

[Table 3](#t3-ehp0115-000769){ref-type="table"} presents the city-specific incidence rates for the three outcomes. In total, the incidence rates were 0.091 for death, 0.054 for CHF admission, and 0.027 for subsequent MI. The incidence rates among all cities were examined by year ([Table 4](#t4-ehp0115-000769){ref-type="table"}); these were higher in the first 5 years but changed little during the following years, justifying the use of three categories to describe the time period.

We found significant associations in the three survival analyses adjusting for confounders ([Table 5](#t5-ehp0115-000769){ref-type="table"}), with a hazard ratio for the sum of the distributed lag for mortality of 1.3 \[95% confidence interval (CI), 1.2--1.5\] per 10μg/m^3^ PM~10~, a hazard ratio of 1.4 (95% CI, 1.2--1.7) for CHF, and a hazard ratio of 1.4 (95% CI, 1.1--1.8) per 10 μg/m^3^ PM~10~ for a new hospitalization for MI. The distributed lag model shows greater effects at lags 1 and 2 exposure, with an overall effect considerably larger than for a single year.

[Table 6](#t6-ehp0115-000769){ref-type="table"} presents the results of the sensitivity analyses. When we restricted the mortality and CHF analysis to subjects with a second MI with follow-up beginning after the occurrence of their second MI, the effect of PM~10~ for the distributed lag model showed an HR of 1.3 (95% CI, 1.15--1.55) in the mortality cohort and an HR of 1.4 (95% CI, 1.22--1.65) in the CHF cohort. Including only those subjects who were admitted for their primary MI between 1985 and 1996, that is, with at least 3 years of follow-up, we found higher estimates than the main results reported in [Table 5](#t5-ehp0115-000769){ref-type="table"}.

In [Table 6](#t6-ehp0115-000769){ref-type="table"} we also present the result of the sensitivity analysis in which we modified the definition of the cohort. For the distributed lag, we found an HR for mortality of 1.3 (95% CI, 1.15--1.4) per 10 μg/m^3^ PM~10~; this HR is similar to the main result in [Table 5](#t5-ehp0115-000769){ref-type="table"}.

[Figure 1](#f1-ehp0115-000769){ref-type="fig"} shows the results of the analysis of effect modification by sex and age groups (65--75 years of age and ≥ 76 years). We did not find effect modification by sex, but we did find a higher effect in the older age group. Following the method of [@b40-ehp0115-000769] to determine whether the difference between the age groups was significant, we found a *p*-value for mortality of 0.064, whereas the *p*-value for subsequent MI and CHF was 0.082.

We used meta-regression ([@b4-ehp0115-000769]) to examine predictors of heterogeneity across city ([Table 7](#t7-ehp0115-000769){ref-type="table"}), and we found that most of the predictors were not significant as modifiers of the PM~10~ effect.

Discussion
==========

We found a significant effect of long-term exposure to airborne particles on the risk of death, progression to heart failure, and a subsequent MI in a large multicity study of subjects discharged alive following an acute MI. This association was not due to differences between cities in exposure, but resulted from the association of year-to-year changes in mortality risk with year-to-year changes in exposure. We found that association persisted for several years of lag, but was falling off by lag 3.

Although several previous studies have reported an association of PM with mortality in survival analysis, this is the first long-term study that investigated persons discharged alive following an acute MI and showed that persons who survive an MI are at risk of death in response to subsequent particle exposure. The present study is the first large cohort study focused on the elderly.

One key difference between the present study and previous cohorts comes from the source of variation in exposure. In the other cohort studies, the source of exposure variation is across geographic area. For example, the ACS study ([@b47-ehp0115-000769]) contrasted covariate-adjusted survival in each city with long-term average pollution in that city. Using such an approach, unmeasured factors that vary across city are potential confounders. For example, substantial geographic variability in the use of cardiovascular medication has been reported in a number of studies, and this was not controlled in previous cohort studies. In the present study the basic analysis was conducted within each city, and exposure variation comes from temporal changes in pollution concentration. This eliminates those potential confounders as a concern. By focusing on 12-month average exposures, it also eliminates the potential confounding by short-term weather factors that are an issue in time-series studies. Obviously, factors that fluctuate from year to year within each city are potential confounders in this study design. The advantage of this approach is that it allows us to use an analytical methodology with different vulnerabilities to confounding than in previous studies; to determine whether an association between PM and mortality risk persists; and to examine an intermediate time period of exposure---in contrast to the use of daily exposure in time-series studies---and exposure over many years in other cohorts.

The use of longitudinal rather than cross-sectional exposure gradients in this study may also explain some of the differences in effect size estimates, because the variation in central station monitoring and personal exposure over time may be more correlated than similar variations over space. Moreover, the ACS study ([@b47-ehp0115-000769]) used monitors within the multicounty metropolitan areas to assign exposure, whereas our subjects are matched to monitors in the same city or county. A recent reanalysis of ACS data restricting to persons living in the same county of the monitor reported a larger risk ([@b47-ehp0115-000769]; [@b60-ehp0115-000769]).

The sensitivity analysis in the present study showed that subjects with a second MI have a higher risk of a PM-associated subsequent death. Hence, this appears to represent a particularly susceptible group.

In a recent case--crossover study examining this association, [@b2-ehp0115-000769] reported much smaller relative risks (1.02; 95% CI, 0.99--1.04). In another case--crossover study ([@b63-ehp0115-000769]) on 21 U.S. cities, we analyzed the short-term effect of PM~10~ on the MI hospitalization in these cities. In that analysis, we also found a smaller relative risk (1.007; 95% CI, 1.003--1.01). Although part of the association reported here may be acute, the evidence indicates cumulative exposure over a year or more elevates risk above and beyond the effects of acute exposure.

We observed a high degree of heterogeneity among the cities. In multicities time-series studies of short-term effect of air pollution on health, heterogeneity has been found among cities ([@b24-ehp0115-000769]; [@b31-ehp0115-000769]; [@b51-ehp0115-000769]). Heterogeneity has been attributed to, for example, differences in particle characteristics, ventilation rates of buildings, average PM~10~ concentrations, and social conditions. Previously published cohort studies could not address the issue of heterogeneity because the studies were essentially cross-sectional; the source of exposure variation was across geographic area. This is the first long-term study to show significant heterogeneity among cities in response to long-term exposure, and the cause of this heterogeneity needs to be determined.

This analysis advances the field *a*) by reporting an association between particle exposure and survival in a cohort study of MI survivors that eliminates geographic variation in risk factors as a confounder, but where exposure variation comes from temporal changes in pollution concentration; and *b*) by focusing on associations on an intermediate time scale. If PM increases progression of atherosclerosis ([@b28-ehp0115-000769]; [@b57-ehp0115-000769]) or impairs endothelial function ([@b8-ehp0115-000769]) or autonomic function ([@b32-ehp0115-000769]; [@b38-ehp0115-000769]), these changes may have greater impact in populations with greater underlying impairment, such as the elderly.

A primary candidate for explaining these risks must be the acute MI itself ([@b3-ehp0115-000769]; [@b18-ehp0115-000769]; [@b22-ehp0115-000769]). Subjects surviving MIs have enhanced risk of dying and decreased heart rate variability ([@b34-ehp0115-000769]), and are likely to have greater susceptibility to subsequent insults.

This possibility of multiple pathways to mortality makes it plausible that the all-cause mortality risk might exceed the risk of specific cardiac events, as we observe for subsequent MI. For example, PM has been associated with arrhythmias ([@b44-ehp0115-000769]), pneumonia ([@b64-ehp0115-000769]), and COPD ([@b52-ehp0115-000769]), creating potential additional pathways by which exposure could increase mortality risk independent of MI risk.

One limitation of the present study is that Medicare does not provide the underlying cause of death. If the cause of death were available, we could understand better the possible pathways.

Future studies examining cohorts with more detailed clinical data on the MI survivors should be fruitful. The increased risk of heart failure following the MI also suggests that further evaluation of this outcome is warranted.

The present study presents additional limitations, the main one being the absence of information on subject characteristics such as smoking, body mass index, or medicine use, and information on whether the patients migrated out of the study areas after their last Medicare contact. However, we were able to adjust for other important characteristics such as age, race, sex, the type of MI, and previous and secondary diagnoses. Missing those other characteristics would only confound the association with air pollution if they were correlated with pollution. However, we conducted a city-specific analysis to remove location-specific differences in the analyses. Hence, differences across cities in smoking rates, for example, cannot confound the association, because only the temporal variability in pollution within city contributes to the association. Smoking could only confound this association if year-to-year variations in smoking rates within city covaried with year-to-year variations in PM~10~ concentrations. Moreover, we examined the emphysema death rate in persons \> 65 years of age as an effect modifier because it is associated with smoking history in the population, and found that it did not modify the PM-associated risk. Thus, smoking is unlikely to be a confounder in our study.

Our findings that both subsequent MIs and CHF admissions, as well as mortality risk, are elevated suggests that multiple pathways are involved in the particle effects.

Other human and animal studies ([@b16-ehp0115-000769]) have shown associations between particulate pollution and changes in heart rate variability ([@b17-ehp0115-000769]; [@b32-ehp0115-000769]; [@b49-ehp0115-000769]); increases in plasma viscosity ([@b42-ehp0115-000769]), C-reactive protein ([@b7-ehp0115-000769]; [@b43-ehp0115-000769]; [@b48-ehp0115-000769]), plasma fibrinogen ([@b15-ehp0115-000769]), white blood cell counts ([@b50-ehp0115-000769]; [@b54-ehp0115-000769]), blood pressure ([@b20-ehp0115-000769]; [@b33-ehp0115-000769]; [@b62-ehp0115-000769]), and oxidative stress ([@b5-ehp0115-000769]; [@b7-ehp0115-000769]; [@b55-ehp0115-000769]); decreases in plaque stability ([@b57-ehp0115-000769]); or occurrence of thrombotic complications after exposure to pollutants ([@b37-ehp0115-000769]). In a recent study [@b38-ehp0115-000769] reported that PM was associated with flow-mediated dilation of the brachial arteries.

Many of these associations are with acute exposure, not long-term exposures such as those used in the present study. Nevertheless, the associations suggest that the hypotheses to explain the potential mechanisms for the particle effects might involve systemic inflammation, changes in autonomic function, or oxidative stress capable of influencing both cardiovascular and pulmonary physiology.

Our findings suggest that persons surviving an MI are at risk from exposure to particulate pollution. This is a large group, and hence this finding has substantial public health implications. Our results also suggest that it would be beneficial to examine this population in mechanistic studies.

This study was supported by the U.S. Environmental Protection Agency (EPA)/Harvard Center on Ambient Particle Health Effects EPA PM Center (U.S. EPA grant R827353).
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###### 

Characteristics of the study population among residents of 21 U.S. cities.

  Characteristic                     No. of events   Percent   Mean (5th--95th percentiles)
  ---------------------------------- --------------- --------- ------------------------------
  MI                                 196,131                   
  Failure                                                      
   Deaths                            89,249          45.5      
   CHF                               33,764          17.2      
   Subsequent MI                     22,552          11.5      
  Baseline characteristics                                     
   Age                                                         76.1 (66.5--89.1)
   Sex                                                         
    Male                             98,822          50.4      
    Female                           97,309          49.6      
   Race                                                        
    White                            165,549         84.4      
    Black                            19,759          10.1      
    Other                            10,823          5.5       
   No. of days in coronary care                                1.3 (0--6.5)
   No. of days in intensive care                               1.5 (0--6.5)
    Type of MI                                                 
    Anterolateral wall               10,088          5.1       
    Other anterior wall              37,993          19.4      
    Inferolateral wall               6,434           3.3       
    Inferoposterior wall             4,291           2.2       
    Other inferior wall              44,923          22.9      
    Other lateral wall               5,326           2.7       
    True posterior wall infarction   2,009           1.0       
    Subendocardial infarction        66,628          34.0      
    Other specified sites            3,951           2.0       
    Unspecified sites                14,488          7.4       
  Secondary or previous diagnoses                              
    COPD                             28,509          14.5      
    Diabetes                         44,686          22.8      
    Hypertension                     72,154          36.8      
   Previous admissions                                         
    Atrial fibrillation              11,374          5.8       

###### 

City-specific counts of hospital admissions for MI, second MI, first CHF, and deaths and for distribution of PM~10~.

                                                                 PM~10~[a](#tfn1-ehp0115-000769){ref-type="table-fn"} (%)          
  ---------------------- -------- -------- ------- ------- ----- ---------------------------------------------------------- ------ ------
  Birmingham, AL         8,927    4,281    1,814   1,028   120   22.8                                                       27.0   38.2
  Boulder, CO            1,117    434      176     97      17    18.0                                                       20.6   28.9
  Canton, OH             4,788    2,061    797     594     53    22.1                                                       25.2   28.4
  Chicago, IL            42,091   20,333   7,673   5,130   632   29.5                                                       33.4   38.5
  Cincinnati, OH         7,961    3,778    1,381   906     115   25.5                                                       30.7   38.2
  Cleveland, OH          16,648   7,767    3,140   1,899   221   35.2                                                       37.6   42.5
  Colorado Springs, CO   2,054    672      282     173     32    18.4                                                       21.0   24.9
  Columbus, OH           7,859    3,574    1,370   1,044   92    25.6                                                       28.5   31.6
  Denver, CO             3,919    1,551    546     357     64    26.6                                                       28.9   36.5
  Detroit, MI            18,437   8,490    3,439   2,098   264   28.0                                                       31.3   37.9
  Honolulu, HI           4,528    1,952    633     484     91    14.8                                                       16.3   18.7
  Houston, TX            10,885   4,764    1,812   975     196   26.0                                                       29.7   32.3
  Minneapolis, MN        10,123   3,962    1,360   1,019   176   22.3                                                       24.7   31.8
  Nashville, TN          4,081    1,877    697     449     59    27.1                                                       30.2   38.5
  New Haven, CT          9,232    4,245    1,447   1,119   118   22.2                                                       24.0   29.3
  Pittsburg, PA          20,663   10,007   3,653   2,800   233   25.2                                                       29.5   34.3
  Provo/Orem, UT         1,504    535      258     136     18    26.3                                                       32.4   38.5
  Salt Lake City, UT     3,535    1,233    425     256     61    28.2                                                       34.1   43.3
  Seattle, WA            9,674    4,011    1,325   921     167   16.0                                                       22.6   31.7
  Steubenville, OH       2,502    1,130    499     302     24    26.4                                                       33.9   37.7
  Youngstown, OH         5,603    2,592    1,037   765     61    27.2                                                       29.2   33.3

Distribution of the individually assigned 1-year PM10 mean in each city.

Population ≥ 65 years of age (× 1,000).

###### 

Accrued person-time and incidence rate for the three survival analyses.

                         Person-years   Incidence rate                             
  ---------------------- -------------- ---------------- --------- ------- ------- -------
  Birmingham, AL         44,672         28,995           39,495    0.120   0.063   0.026
  Boulder, CO            6,292          4,014            5,305     0.084   0.044   0.018
  Canton, OH             23,826         15,333           20,336    0.108   0.052   0.029
  Chicago, IL            207,151        125,216          180,216   0.123   0.061   0.028
  Cincinnati, OH         39,967         25,530           35,255    0.118   0.054   0.026
  Cleveland, OH          83,790         52,392           72,310    0.116   0.060   0.026
  Colorado Springs, CO   10,475         7,813            9,430     0.080   0.036   0.018
  Columbus, OH           37,725         24,977           33,535    0.120   0.055   0.031
  Denver, CO             22,424         15,187           20,178    0.084   0.036   0.018
  Detroit, MI            87,612         55,024           74,111    0.123   0.063   0.028
  Honolulu, HI           21,831         14,842           19,632    0.113   0.043   0.025
  Houston, TX            52,910         36,734           46,250    0.113   0.049   0.021
  Minneapolis, MN        51,318         34,124           46,421    0.096   0.040   0.022
  Nashville, TN          20,710         14,039           18,168    0.113   0.050   0.025
  New Haven, CT          46,935         28,516           40,926    0.113   0.051   0.027
  Pittsburg, PA          101,145        63,399           82,726    0.124   0.058   0.034
  Provo/Orem, UT         8,138          5,401            6,798     0.081   0.048   0.020
  Salt Lake City, UT     19,021         13,236           17,136    0.080   0.032   0.015
  Seattle, WA            52,168         34,519           46,465    0.094   0.038   0.020
  Steubenville, OH       11,674         6,986            9,311     0.123   0.071   0.032
  Youngstown, OH         27,146         16,902           23,182    0.120   0.061   0.033
  Total                  976,930        623,179          847,186   0.091   0.054   0.027

###### 

Accrued person-years, number of deaths, and incidence rate (IR) across all cities by year for the mortality cohort.

  Year   Person-years   No. of deaths   IR
  ------ -------------- --------------- -------
  1986   10,015         1,423           0.142
  1987   22,094         2,808           0.127
  1988   32,640         3,675           0.113
  1989   41,852         4,173           0.100
  1990   50,173         4,786           0.095
  1991   59,419         5,581           0.094
  1992   67,713         6,223           0.092
  1993   76,769         6,711           0.087
  1994   85,574         7,709           0.090
  1995   93,209         8,427           0.090
  1996   100,260        8,803           0.088
  1997   107,150        9,152           0.085
  1998   113,019        9,617           0.085
  1999   117,043        10,161          0.087

###### 

HR and 95% CI for 10-μg/m^3^ increase in PM~10~ for the year of failure and for the distributed lag from the year of failure up to 3 previous years.

  Failure                  HR     95% CI       *p*-Values
  ------------------------ ------ ------------ ------------
  Death                                        
   PM~10~ annual           1.11   1.05--1.19   0.001
   Distributed lag model                       
    Lag 0                  1.04   0.96--1.14   0.336
    Lag 1                  1.07   0.99--1.14   0.070
    Lag 2                  1.14   1.10--1.18   0.000
    Lag 3                  1.06   0.99--1.12   0.077
    Sum lags 0--3          1.34   1.17--1.52   0.000
  CHF                                          
   PM~10~ annual           1.11   1.03--1.21   0.009
   Distributed lag model                       
    Lag 0                  1.09   1.01--1.18   0.030
    Lag 1                  1.09   1.01--1.19   0.038
    Lag 2                  1.13   1.02--1.25   0.014
    Lag 3                  1.04   0.97--1.12   0.260
    Sum lags 0--3          1.41   1.19--1.66   0.000
  Second MI                                    
   PM~10~ annual           1.17   1.05--1.31   0.003
   Distributed lag model                       
    Lag 0                  1.09   0.92--1.30   0.325
    Lag 1                  1.12   0.97--1.30   0.108
    Lag 2                  1.15   1.08--1.23   0.000
    Lag 3                  1.01   0.94--1.09   0.783
    Sum lags 0--3          1.43   1.12--1.82   0.005

Models controlled for season, days of coronary care and intensive care, previous diagnosis for atrial fibrillation, and secondary or previous diagnoses for COPD, diabetes, and hypertension; we adjusted for time period, age, sex, race, and type of MI as stratification variables.

###### 

HR and 95% CI for 10 μg/m^3^ increase in PM~10~ (sum of previous 3 years distributed lag) for the sensitivity analyses.

                                                                                           HR     95% CI       *p*-Values
  ---------------------------------------------------------------------------------------- ------ ------------ ------------
  Death                                                                                                        
   Subjects with subsequent MI[a](#tfn4-ehp0115-000769){ref-type="table-fn"}               1.33   1.15--1.55   0.000
   Subjects admitted between 1985 and 1996[b](#tfn5-ehp0115-000769){ref-type="table-fn"}   1.45   1.26--1.68   0.000
   Second definition of cohort[c](#tfn6-ehp0115-000769){ref-type="table-fn"}               1.29   1.15--1.44   0.000
  CHF                                                                                                          
   Subjects with subsequent MI[a](#tfn4-ehp0115-000769){ref-type="table-fn"}               1.42   1.22--1.65   0.000
   Subjects admitted between 1985 and 1996[b](#tfn5-ehp0115-000769){ref-type="table-fn"}   1.51   1.26--1.81   0.000
  Subsequent MI                                                                                                
   Subjects admitted between 1985 and 1996[b](#tfn5-ehp0115-000769){ref-type="table-fn"}   1.62   1.23--2.13   0.001

Follow-up started after subsequent MI.

Includes only primary admission for MI during 1985 and 1996.

Yearly follow-up and 12-month average PM~10~ exposure for each subject for each subsequent year of follow-up starting from the month of the index admission until censoring or failure.

###### 

Modification of the PM~10~ association in the three survival analyses by city characteristics across 21 U.S. cities expressed as HR and 95% CI for 10-μg/m^3^ increase in PM~10~ (distributed lag) estimated at the 25th percentile and the 75th percentile of the effect modifier.

                                                                 HR at the 25% percentile   HR at the 75% percentile                                
  ------------------------------------------------------- ------ -------------------------- -------------------------- ------------ -------- ------ ------------
  Population ≥ 65 years of age in poverty status (%)                                                                                                
   Death                                                  0.60   8.0                        1.34                       1.06--1.70   11.4     1.27   1.05--1.53
   CHF                                                    0.83                              1.36                       1.05--1.75            1.32   1.08--1.62
   MI                                                     0.61                              1.29                       0.91--1.82            1.19   0.91--1.56
  Annual mortality rate for emphysema ≥ 65 years of age                                                                                             
   Death                                                  0.57   32.9                       1.33                       1.07--1.67   47.6     1.27   1.04--1.54
   CHF                                                    0.37                              1.42                       1.12--1.79            1.30   1.06--1.60
   MI                                                     0.97                              1.26                       0.91--1.73            1.25   0.94--1.66
  Mean PM~10~                                                                                                                                       
   Death                                                  0.60   25.5                       1.25                       1.01--1.55   32.1     1.33   1.07--1.65
   CHF                                                    0.74                              1.36                       1.08--1.72            1.30   1.03--1.64
   MI                                                     0.04                              1.02                       0.76--1.37            1.43   1.08--1.91
  IQR PM~10~                                                                                                                                        
   Death                                                  0.70   3.3                        1.31                       1.07--1.62   5.5      1.26   1.02--1.56
   CHF                                                    0.38                              1.40                       1.12--1.74            1.26   1.01--1.58
   MI                                                     0.28                              1.12                       0.83--1.50            1.33   0.98--1.79
  Population density                                                                                                                                
   Death                                                  0.67   594.8                      1.33                       1.06--1.67   2076.9   1.27   1.05--1.54
   CHF                                                    0.75                              1.30                       1.02--1.66            1.35   1.10--1.65
   MI                                                     0.74                              1.17                       0.84--1.64            1.23   0.93--1.62

IQR, interquartile range.
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